tetano
Editor, Senior Moderator
Nat Commun
. 2020 Nov 12;11(1):5744.
doi: 10.1038/s41467-020-19481-7.
Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
Ed Slot[SUP] 1 2 [/SUP], Boris M Hogema[SUP] 3 4 [/SUP], Chantal B E M Reusken[SUP] 5 6 [/SUP], Johan H Reimerink[SUP] 5 [/SUP], Michel Molier[SUP] 3 [/SUP], Jan H M Karregat[SUP] 7 [/SUP], Johan IJlst[SUP] 8 [/SUP], Věra M J Novotn?[SUP] 9 [/SUP], Ren? A W van Lier[SUP] 10 11 [/SUP], Hans L Zaaijer[SUP] 12 13 14 [/SUP]
Affiliations
Abstract
The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18-72 years), and (iv) antibodies were significantly more often present in younger people (18-30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place.
. 2020 Nov 12;11(1):5744.
doi: 10.1038/s41467-020-19481-7.
Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands
Ed Slot[SUP] 1 2 [/SUP], Boris M Hogema[SUP] 3 4 [/SUP], Chantal B E M Reusken[SUP] 5 6 [/SUP], Johan H Reimerink[SUP] 5 [/SUP], Michel Molier[SUP] 3 [/SUP], Jan H M Karregat[SUP] 7 [/SUP], Johan IJlst[SUP] 8 [/SUP], Věra M J Novotn?[SUP] 9 [/SUP], Ren? A W van Lier[SUP] 10 11 [/SUP], Hans L Zaaijer[SUP] 12 13 14 [/SUP]
Affiliations
- PMID: 33184284
- DOI: 10.1038/s41467-020-19481-7
Abstract
The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18-72 years), and (iv) antibodies were significantly more often present in younger people (18-30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place.